Related Experiment Videos
Androgen concentrations in expressed prostatic secretions: no correlation with tissue levels
F K Habib1, C M Goodman, C Buck
1University Department of Surgery (WGH), Western General Hospital, Edinburgh, UK.
This study compared androgen levels in prostatic fluid (EPS) with those in prostate tissue from patients with benign prostatic hyperplasia (BPH). Researchers found that androgen concentrations in EPS were much higher than in tissue. Despite this, the levels in fluid did not reflect those in tissue. The study also measured zinc in EPS and tissue but found no correlation between the two. However, zinc in EPS was strongly linked to testosterone and DHT in the same fluid. These findings suggest that EPS androgen levels cannot be used to predict tissue concentrations. The study highlights the need for caution when interpreting prostatic fluid androgen data.
Area of Science:
- Andrology and prostate physiology
- Endocrinology of steroid hormones
- Urological biomarker research
Background:
Prior research has shown that androgen levels in prostate tissue are linked to benign prostatic hyperplasia (BPH). However, it was unclear whether these levels are reflected in prostatic fluid. Established knowledge includes the role of testosterone and dihydrotestosterone (DHT) in prostate growth. A gap exists in understanding how fluid and tissue concentrations relate. This uncertainty motivated a direct comparison of androgen levels in expressed prostatic secretions (EPS) and BPH tissue. No prior work had resolved whether EPS androgen levels mirror those in tissue. Researchers sought to clarify this relationship. The study aimed to bridge a critical knowledge gap in prostate hormone dynamics. Understanding this could refine biomarker use in prostate health assessments.
Purpose Of The Study:
The study aimed to compare androgen concentrations in expressed prostatic secretions (EPS) with those in benign prostatic hyperplasia (BPH) tissue. The specific problem addressed was whether EPS androgen levels reflect those in tissue. Motivation came from the need to determine if EPS could serve as a reliable fluid-based biomarker. The authors proposed to measure testosterone and DHT in EPS and BPH tissue from the same patients. This approach allowed direct correlation between fluid and tissue samples. The study sought to clarify if EPS androgen levels are predictive of tissue concentrations. No prior work had established this link definitively. The findings could influence diagnostic approaches in prostate health.
Main Methods:
The study involved measuring testosterone and DHT in expressed prostatic secretions (EPS) and benign prostatic hyperplasia (BPH) tissue from 19 patients. Dry weight concentrations were used for standardization. Hormone levels were quantified using biochemical assays. The researchers compared EPS and tissue concentrations to assess correlation. Zinc levels were also measured in both EPS and BPH tissue. Statistical analysis included correlation coefficients and p-values. The study focused on androgen and zinc relationships in both fluid and tissue. No prior methods had directly compared EPS and tissue androgen profiles in this manner.
Main Results:
Androgen concentrations in expressed prostatic secretions (EPS) were significantly higher than in BPH tissue. Testosterone in EPS was 106.7 ng/g dry weight compared to 7.56 ng/g in tissue. DHT in EPS was 54.2 ng/g dry weight versus 10.54 ng/g in tissue. Despite high EPS androgen levels, no correlation was found with tissue concentrations. Testosterone and DHT in EPS showed a strong correlation (r = 0.89; P < 0.01). Zinc levels in EPS were not correlated with those in BPH tissue. However, EPS zinc correlated with both EPS testosterone (r = 0.73; P < 0.01) and DHT (r = 0.69; P < 0.01). These findings suggest EPS androgen levels are not predictive of tissue levels.
Conclusions:
The authors concluded that androgen concentrations in expressed prostatic secretions (EPS) do not reflect those in benign prostatic hyperplasia (BPH) tissue. EPS testosterone and DHT levels were much higher than in tissue. The strong correlation between EPS testosterone and DHT was not mirrored in tissue. Zinc levels in EPS were not related to those in tissue. However, EPS zinc correlated with both androgens in EPS. These findings suggest that EPS may not serve as a reliable biomarker for tissue androgen levels. The study highlights the need for caution in interpreting EPS androgen data. The authors propose further research to clarify the functional significance of these findings.
Frequently Asked Questions
According to the authors, androgen concentrations in expressed prostatic secretions (EPS) do not reflect those in benign prostatic hyperplasia (BPH) tissue.
The researchers found that zinc in EPS correlated strongly with testosterone (r = 0.73) and DHT (r = 0.69) in the same fluid.
The authors propose that this suggests EPS androgen levels cannot be used as a proxy for tissue concentrations in BPH.
The study used correlation coefficients and p-values to assess relationships between EPS and tissue androgen levels.
EPS testosterone was 106.7 ng/g dry weight compared to 7.56 ng/g in tissue; DHT was 54.2 ng/g in EPS versus 10.54 ng/g in tissue.
The authors suggest that EPS may not serve as a reliable biomarker for tissue androgen concentrations in benign prostatic hyperplasia.